Cardiac Pacemaker Market Determined By Market
Concentration Rate, New Entrants, Products, Services And
Solutions 2026
Cardiac pacemaker is a medical device placed in the chest to control abnormal heart rhythm of
the patient by using electrical pulses, which prompt the heart to contract and pump blood.
Pacemakers have ability to monitor and record heart's rhythm and electrical activity. Cardiac
pacemaker is composed of a small titanium encased pulse generator, which contains a lithium
battery and electrical circuitry attached to one, two, or three leads, which are inserted into the
heart. Pacemaker pulse generators should be checked twice to thrice a year and must be
replaced every five to ten years. The technical advantages of lithium iodine battery in terms of
its longevity, adaptable shapes and sizes, light weight, no gas generation, corrosion resistance,
and excellent current drain characteristics makes the cardiac pacemakers suitable to last as long
as the expected lifetime.
The global cardiac pacemaker market was valued at US$ 5,972.2 million in 2017, and is
expected to witness a CAGR of 7.3% over the forecast period (2018–2026).
Download Free PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/1765
Cardiac Pacemaker Market Dynamics:
Increasing incidence of cardiovascular diseases worldwide is fueling growth of the cardiac
pacemaker market. According to the Centre for Disease Control and Prevention (CDC)
foundation, 2015, around 800,000 Americans die due to stroke and other cardiovascular
diseases. Moreover, increasing number of geriatric population across the various regions
worldwide along with high prevalence of heart disease is expected to propel demand for
implantable cardiac pacemakers in the near future. According to the data published in the
Journal of the Formosan Medical Association, in November 2016, around half of the world
population living in Asia is geriatric population and it is growing at faster rate, which is
increasing burden of Atrial Fibrillation (AF) in Asia. According to the same source, in 2050,
around 72 million people are projected to suffer from AF in Asia, which is expected to be more
than double the combined numbers of patients from Europe and the U.S.